ZIG
NVCR icon

Zuckerman Investment Group’s NovoCure NVCR Stock Holding History

Zuckerman Investment Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,000
Closed -$206K – 151
2024
Q2 		$206K Hold
12,000
– – 0.02% 137
2024
Q1 		$188K Buy
+12,000
New +$176K 0.02% 137

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Zuckerman Investment Group's NVCR Position: Q3 2024 in Review

Zuckerman Investment Group sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 12,000 shares — an estimated $206K sold.

Zuckerman Investment Group first reported a position in NVCR in Q1 2024 and held it in 2 quarters. The position peaked at $206K in Q2 2024. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Zuckerman Investment Group reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Zuckerman Investment Group sold 12,000 NovoCure shares in Q3 2024, an estimated $206K.
  • Zuckerman Investment Group first reported a position in NovoCure in Q1 2024 and held it in 2 quarters.
  • Zuckerman Investment Group's NovoCure position peaked at $206K in Q2 2024.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Zuckerman Investment Group's 13F filing for Q3 2024, filed 13 Nov 2024.